The Life Sciences team represented Aktis Oncology in its License, Research and Collaboration Agreement with Eli Lilly and Company under which the parties will engage in a multi-target discovery collaboration to generate anticancer radiopharmaceuticals using Aktis' novel miniprotein technology platform.
Under the terms of the agreement, Aktis will receive a $60 million upfront cash payment for the collaboration in addition to an equity investment in Aktis by Lilly. In addition, Aktis will be eligible to receive up to an additional $1.1 billion in potential preclinical, clinical, regulatory and commercial milestones, as well as tiered royalties. In exchange, Lilly will receive worldwide rights to develop radiopharmaceutical therapeutic and diagnostic products discovered by Aktis on a defined set of targets selected by Lilly.
Aktis is a biotechnology company pioneering the discovery and development of novel targeted alpha radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital, the company has developed proprietary platforms to generate tumor targeting agents with ideal properties for alpha radiotherapy.
The Goodwin team was led by Richard Hoffman, EA Weeks and Chris Zhong with invaluable assistance from Cathy McCarty (IP), Dan Karelitz, (Tax), Susan Lee (FDA), Alex Valenti (Litigation) and Alex Hernandez (IPTS).
For additional details on the agreement, please read the press release.